Crinetics Pharmaceuticals
Tracked across 4 events · 86 articles · First seen Jul 06, 2026 · Last active Aug 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Crinetics is being acquired by Vertex for $85 per share, providing shareholders with a premium. Its key assets include approved drug Palsonify and late-stage candidate atumelnant.
Jul 06, 2026 · 34 articles
Business
Impact: Crinetics is being acquired by Vertex for $10 billion, adding endocrine disorder treatments to Vertex's portfolio. The deal is expected to close in Q3 and is likely to provide a significant premium to Crinetics shareholders.
Aug 03, 2026 · 7 articles
Regulatory
Impact: Target of investigation regarding its sale to Vertex Pharmaceuticals; shareholders may receive $85 per share, but the inquiry could affect the deal.
Jul 20, 2026 · 20 articles
Business
Impact: Crinetics Pharmaceuticals was acquired by Vertex, contributing to the favorable M&A environment.
Jul 06, 2026 · 25 articles
Vertex Pharmaceuticals
acquisition target
↔
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is the target of an acquisition by Vertex Pharmaceutic
Vertex Pharmaceuticals
acquirer
↔
Crinetics Pharmaceuticals
Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion to
ERGEN INTELLIGENCE
Track Crinetics Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard